Capricor Therapeutics to Present at PPMD Annual Conference
28 juin 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, June 28, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics’ (NASDAQ:CAPR) chief medical officer, Deborah Ascheim, M.D., will present a corporate overview at the Parents Project Muscular...
Capricor Therapeutics to Present at the 2018 BIO International Convention in Boston
29 mai 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, May 29, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other rare disorders,...
Capricor Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
10 mai 2018 16h00 HE
|
Capricor Therapeutics, Inc.
HOPE-2 Clinical Trial is Currently Enrolling Patients Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, May 10, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a...
Capricor Therapeutics to Present First Quarter 2018 Financial Results and Corporate Update on May 10
04 mai 2018 08h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, May 04, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
Capricor to Present on Exosomes at the Plenary Session of the International Society for Cellular Therapy in Montreal
03 mai 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, May 03, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that Linda Marbán, Ph.D., Capricor president and CEO, will provide a presentation on exosomes at...
Capricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model
19 avr. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, April 19, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that researchers found that repeat dosing of the company’s proprietary cellular therapy yields an...
Capricor Presents Fourth Quarter and Full Year 2017 Financial Results and Corporate Update
14 mars 2018 16h00 HE
|
Capricor Therapeutics, Inc.
Planning to Initiate HOPE-2 Clinical Trial To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, March 14, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics...
Capricor Therapeutics to Present Fourth Quarter and Full Year 2017 Financial Results and Corporate Update on Wednesday, March 14
08 mars 2018 16h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, March 08, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
Capricor to Host Key Opinion Leader Lunch on March 9
28 févr. 2018 08h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced it will host a Key Opinion Leader Lunch in New York City on March 9 featuring four distinguished...
New Published Study Reports Cardiosphere-Derived Cells Improved Skeletal and Cardiac Muscle Function in Mouse Model of Duchenne Muscular Dystrophy
22 févr. 2018 13h23 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced the online publication in Stem Cell Reports of a new study by researchers at the Smidt Heart...